LifeSignals and Renew Health Announce Merger
LifeSignals has announced it will merge with Renew Health resulting in a new company, LifeSignals Group. The company will continue to develop wireless biosensor technology along with Renew's UltraLinq cloud-based cardiology PACS platform business and the Zensor + cardiac analytics software business and will be led by LifeSignals CEO, Surendar Magar, whilst Renew Health's CEO, Ravinder Sajwan, will join the Board of Directors.
Surendar Magar said of the merger, “I am delighted to see this merger come to fruition. Combining the assets of both parties brings the scale and resources required for LifeSignals to accelerate its vision of promoting multiparameter clinical-grade wireless biosensor patches and replace the billions of “wired” biosensors that currently dominate the clinical monitoring arena. Overall, the combination of our wireless proprietary smart biosensor technology with the flexible cloud-based analytics, will enable patients and healthcare providers to receive potentially life-saving, real-time analysis of health data at a level that did not previously exist.”
Ravinder Sajwan added, “The Renew Group has long recognised the potential of LifeSignals to lead wireless biosensor adaptation on a global scale due to the unmatched power of its processor technology. Having made major investments in the connected health technologies that are complementary to LifeSignals biosensors, we see it as a natural progression to merge the connected health assets of Renew with LifeSignals, to create LifeSignals Group. Post-merger, Renew will concentrate its resources on the manufacture and global distribution of our unique commercial product portfolio.”
NantHealth's Connected Care to be Acquired by Masimo
Masimo has announced plans to acquire NantHealth's connected care business. Masimo will pay $47.25m for the business and it's medical device products, which include the DCX device connectivity (previously DeviceConX), VCX patient vitals software (previously VitalsConX), the HBox connectivity hub, and Shuttle interface cable. The company hopes the acquisition will help to acheieve their aim of providing more hospitals with connectivity and automation, and allow more innovative noninvasive monitoring.
CEO of Masimo, Joe Kiani, stated, “Through connectivity, predictive algorithms and decision support, we hope to improve the continuum of great care. The connectivity assets we are acquiring are completely in line with our mission as they will help accelerate our internal growth initiatives in this area.”
LABORIE Medical Technologies to Acquire Clinical Innovations
LABORIE Medical Technologies announced it will acquire labour, delivery and neonatal intensive care specialists, Clinical Innovations for $525m.
CEO of Clinical Innovations, Ken Reali, said about the deal “This is a promising deal that will add scale to the overall business. We share a similar vision for the continued growth of Clinical Innovations. The combination of Clinical Innovations and LABORIE will have a positive impact for mothers, babies and healthcare professionals.”
LABORIE is a leading manufacturer of pelvic and gastroenterology medical devices. The company hopes the acquisition will boost its presence within the labour and delivery and NICU industries.
“Acquiring Clinical Innovations marks an important step in the evolution of our business and our continued investment in market-leading technologies for high-growth medical specialties that deliver clinical, access and economic advantages,” said Michael Frazzette, CEO of LABORIE Medical Technologies. “Clinical Innovations, which will form a stand-alone global business unit, immediately provides LABORIE with a strong global presence in the L&D and NICU specialties. The company’s diversified, differentiated product portfolio truly makes a difference for clinicians and their patients.”
Anika Therapeutics to Acquire Arthrosurface and Parcus Medical
Joint therapy specialists, Anika Therapeutics has announced the acquisitions of joint surface and preservation solutions provider, Arthrosurface and sports medicine company, Parcus Medical.
Joseph Darling, President and CEO of Anika Therapeutics said of the acquisitions, “We are very excited about these acquisitions, which are consistent with Anika’s commitment to expanding our portfolio into replacement and regenerative therapies for joint preservation and restoration”
“These acquisitions will significantly enhance our commercial capabilities and infrastructure, diversify our revenue mix and expand our product portfolio and pipeline. Parcus Medical provides direct access to the high-growth ambulatory surgery center market, which will enable Anika to source new revenue streams, and Arthrosurface has an innovative product pipeline and an established direct hybrid sales model, which will accelerate our product platform strategy. Importantly, we are confident that these acquisitions, together with our existing product portfolio, will solidify Anika’s position in the $7 billion sports and regenerative medicine market and strengthen our ability to deliver better patient experiences and drive sustained revenue growth that will ultimately enhance value for shareholders.”